{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:52:55Z","timestamp":1795027975432,"version":"4.10.2"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed\/refractory (r\/r) multiple myeloma, but is hampered by unique side effects that can lengthen hospital stays and increase morbidity. Hematological toxicity (e.g. profound and prolonged cytopenias) represents the most common grade\u2009\u2265\u20093 toxicity and can predispose for severe infectious complications. Here, we examined the utility of the CAR-HEMATOTOX (HT) score to predict toxicity and survival outcomes in patients receiving standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were retrospectively collected from 113 r\/r multiple myeloma patients treated between April 2021 and July 2022 across six international CAR-T centers. The HT score\u2014composed of factors related to hematopoietic reserve and baseline inflammatory state\u2014was determined prior to lymphodepleting chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At lymphodepletion, 63 patients were HT\n                      <jats:sup>low<\/jats:sup>\n                      (score 0\u20131) and 50 patients were HT\n                      <jats:sup>high<\/jats:sup>\n                      (score\u2009\u2265\u20092). Compared to their HT\n                      <jats:sup>low<\/jats:sup>\n                      counterparts, HT\n                      <jats:sup>high<\/jats:sup>\n                      patients displayed prolonged severe neutropenia (median 9 vs. 3\u00a0days, p\u2009&lt;\u20090.001), an increased severe infection rate (40% vs. 5%, p\u2009&lt;\u20090.001), and more severe ICANS (grade\u2009\u2265\u20093: 16% vs. 0%, p\u2009&lt;\u20090.001). One-year non-relapse mortality was higher in the HT\n                      <jats:sup>high<\/jats:sup>\n                      group (13% vs. 2%, p\u2009=\u20090.019) and was predominantly attributable to\u00a0fatal infections. Response rates according to IMWG criteria were higher in HT\n                      <jats:sup>low<\/jats:sup>\n                      patients (\u2265\u2009VGPR: 70% vs. 44%, p\u2009=\u20090.01). Conversely,\u00a0HT\n                      <jats:sup>high<\/jats:sup>\n                      patients exhibited inferior progression-free (median 5 vs. 15\u00a0months, p\u2009&lt;\u20090.001) and overall survival (median 10.5\u00a0months vs. not reached, p\u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data highlight the prognostic utility of the CAR-HEMATOTOX score for both toxicity and treatment response in\u00a0multiple myeloma patients receiving BCMA-directed CAR-T. The score may guide toxicity management (e.g. anti-infective prophylaxis, early G-CSF, stem cell boost) and help\u00a0to identify suitable CAR-T candidates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-023-01465-x","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T10:02:37Z","timestamp":1690797757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":143,"title":["The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma"],"prefix":"10.1186","volume":"16","author":[{"given":"Kai","family":"Rejeski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sesques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Logue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Br\u00e4unlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Cordas dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Theurich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Krackhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"issue":"10297","key":"1465_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"8","key":"1465_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"18","key":"1465_CR3","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726\u201337.","journal-title":"N Engl J Med"},{"key":"1465_CR4","doi-asserted-by":"crossref","unstructured":"Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene Autoleucel, an Anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2022:JCO2200842.","DOI":"10.1016\/j.htct.2021.10.460"},{"issue":"7","key":"1465_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","volume":"29","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Jain MD, Smith EL. Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma. Transplant Cell Ther. 29(7):418\u201328.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"1465_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, Godel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.","journal-title":"J Immunother Cancer"},{"issue":"20","key":"1465_CR7","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","volume":"133","author":"P Karschnia","year":"2019","unstructured":"Karschnia P, Jordan JT, Forst DA, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133(20):2212\u201321.","journal-title":"Blood"},{"issue":"24","key":"1465_CR8","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Perez Perez A, Sesques P, et al. CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed\/refractory large B-cell lymphoma. Blood. 138(24):2499\u2013513.","journal-title":"Blood"},{"issue":"15","key":"1465_CR9","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","volume":"4","author":"T Jain","year":"2020","unstructured":"Jain T, Knezevic A, Pennisi M, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4(15):3776\u201387.","journal-title":"Blood Adv"},{"issue":"24","key":"1465_CR10","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","volume":"6","author":"JM Logue","year":"2022","unstructured":"Logue JM, Peres LC, Hashmi H, et al. Early cytopenias and infections after standard of care idecabtagene vicleucelin relapsed or refractory multiple myeloma. Blood Adv. 6(24):6109\u201319.","journal-title":"Blood Adv"},{"issue":"4","key":"1465_CR11","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3324\/haematol.2019.238634","volume":"106","author":"JM Logue","year":"2020","unstructured":"Logue JM, Zucchetti E, Bachmeier CA, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 106(4):978\u201386.","journal-title":"Haematologica"},{"issue":"13","key":"1465_CR12","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","volume":"4","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn K, Pennisi M, Garcia-Recio M, et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 2020;4(13):3024\u201333.","journal-title":"Blood Adv"},{"issue":"1","key":"1465_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","volume":"131","author":"JA Hill","year":"2018","unstructured":"Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018;131(1):121\u201330.","journal-title":"Blood"},{"issue":"8","key":"1465_CR14","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.2019004000","volume":"136","author":"JA Hill","year":"2020","unstructured":"Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020;136(8):925\u201335.","journal-title":"Blood"},{"issue":"1","key":"1465_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12879-020-05755-4","volume":"21","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Kunz WG, Rudelius M, et al. Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy\u2014a case report. BMC Infect Dis. 2021;21(1):121.","journal-title":"BMC Infect Dis"},{"issue":"27","key":"1465_CR16","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T Consortium. J Clin Oncol. 2020;38(27):3119\u201328.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1465_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/jitc-2021-004475","volume":"10","author":"K Rejeski","year":"2022","unstructured":"Rejeski K, Perez A, Iacoboni G, et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL. J Immunother Cancer. 2022;10(5):66.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"1465_CR18","first-page":"349","volume":"140","author":"WA Bethge","year":"2022","unstructured":"Bethge WA, Martus P, Schmitt M, et al. GLA\/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood. 140(4):349\u201358.","journal-title":"Blood"},{"issue":"7","key":"1465_CR19","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","volume":"25","author":"IW Flinn","year":"2007","unstructured":"Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25(7):793\u20138.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1465_CR20","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried S, Avigdor A, Bielorai B, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019;54(10):1643\u201350.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"1465_CR21","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","volume":"6","author":"KR Juluri","year":"2021","unstructured":"Juluri KR, Wu V, Voutsinas JM, et al. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv. 6(7):2055\u201368.","journal-title":"Blood Adv"},{"issue":"4","key":"1465_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000858","volume":"7","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Blumenberg V, Iacoboni G, et al. Identifying early infections in the setting of CRS with routine and exploratory serum proteomics and the HT10 score following CD19 CAR-T for relapsed\/refractory B-NHL. Hemasphere. 2023;7(4): e858.","journal-title":"Hemasphere"},{"issue":"30","key":"1465_CR23","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline update. J Clin Oncol. 2018;36(30):3043\u201354.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1465_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"1465_CR25","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.3324\/haematol.2021.280189","volume":"107","author":"DMC Dos Santos","year":"2022","unstructured":"Dos Santos DMC, Rejeski K, Winkelmann M, et al. Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 CAR-T in advanced B-cell malignancies. Haematologica. 107(9):2096\u2013107.","journal-title":"Haematologica"},{"issue":"2","key":"1465_CR26","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.bbmt.2015.09.013","volume":"22","author":"JH Young","year":"2016","unstructured":"Young JH, Logan BR, Wu J, et al. Infections after transplantation of bone marrow or peripheral blood stem cells from unrelated donors. Biol Blood Marrow Transplant. 2016;22(2):359\u201370.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"1465_CR27","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"issue":"27","key":"1465_CR28","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1465_CR29","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1182\/blood.2022017015","volume":"140","author":"K Rejeski","year":"2022","unstructured":"Rejeski K, Wu Z, Blumenberg V, et al. Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T for Richter transformed DLBCL. Blood. 140(20):2175\u20139.","journal-title":"Blood"},{"issue":"4","key":"1465_CR30","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985\u20131005.","journal-title":"Leukemia"},{"issue":"2","key":"1465_CR31","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"AJ Novak","year":"2004","unstructured":"Novak AJ, Darce JR, Arendt BK, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004;103(2):689\u201394.","journal-title":"Blood"},{"issue":"8","key":"1465_CR32","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048\u201360.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1465_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36.","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"1465_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000889","volume":"7","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Greco R, Onida F, et al. An international survey on grading, diagnosis, and management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) following CAR T-cell therapy on behalf of the EBMT and EHA. Hemasphere. 2023;7(5): e889.","journal-title":"Hemasphere"},{"key":"1465_CR35","doi-asserted-by":"crossref","unstructured":"Rejeski K, Subklewe M, Aljurf M et al. Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA\/EBMT consensus grading and best practice recommendations. Blood. 2023.","DOI":"10.1182\/blood.2023020578"},{"issue":"7","key":"1465_CR36","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","volume":"6","author":"S Kambhampati","year":"2022","unstructured":"Kambhampati S, Sheng Y, Huang CY, et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2022;6(7):2045\u201354.","journal-title":"Blood Adv"},{"issue":"3","key":"1465_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41409-021-01526-0","volume":"57","author":"R Lievin","year":"2022","unstructured":"Lievin R, Di Blasi R, Morin F, et al. Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma. Bone Marrow Transplant. 57(3):431\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"1465_CR38","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41408-022-00741-2","volume":"12","author":"KC Miller","year":"2022","unstructured":"Miller KC, Johnson PC, Abramson JS, et al. Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. Blood Cancer J. 2022;12(10):146.","journal-title":"Blood Cancer J"},{"issue":"6","key":"1465_CR39","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/s41409-019-0674-2","volume":"55","author":"Q Lin","year":"2020","unstructured":"Lin Q, Liu X, Han L, et al. Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA-CAR-T therapy in patient with relapsed myeloma. Bone Marrow Transplant. 2020;55(6):1203\u20135.","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"1465_CR40","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1182\/bloodadvances.2022007776","volume":"6","author":"K Rejeski","year":"2022","unstructured":"Rejeski K, Burchert A, Iacoboni G, et al. Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy. Blood Adv. 2022;6(16):4719\u201325.","journal-title":"Blood Adv"},{"key":"1465_CR41","first-page":"66","volume":"6","author":"JA Davis","year":"2023","unstructured":"Davis JA, Sborov DW, Wesson W, et al. Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy. Transplant Cell Ther. 2023;6:66.","journal-title":"Transplant Cell Ther"},{"issue":"19","key":"1465_CR42","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke FL, Rossi JM, Neelapu SS, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(19):4898\u2013911.","journal-title":"Blood Adv"},{"issue":"19","key":"1465_CR43","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain MD, Zhao H, Wang X, et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021;137(19):2621\u201333.","journal-title":"Blood"},{"issue":"4","key":"1465_CR44","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","volume":"2","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Themeli M, Usmani SZ. Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma. Blood Cancer Discov. 2021;2(4):302\u201318.","journal-title":"Blood Cancer Discov"},{"issue":"9","key":"1465_CR45","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.clml.2020.03.012","volume":"20","author":"AS Al Saleh","year":"2020","unstructured":"Al Saleh AS, Parmar HV, Visram A, et al. Increased bone marrow plasma-cell percentage predicts outcomes in newly diagnosed multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2020;20(9):596\u2013601.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"1465_CR46","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1365-2141.1983.tb02851.x","volume":"55","author":"M Cavo","year":"1983","unstructured":"Cavo M, Baccarani M, Gobbi M, Lipizer A, Tura S. Prognostic value of bone marrow plasma cell infiltration in stage I multiple myeloma. Br J Haematol. 1983;55(4):683\u201390.","journal-title":"Br J Haematol"},{"issue":"5","key":"1465_CR47","first-page":"257","volume":"10","author":"M Zirakchian Zadeh","year":"2020","unstructured":"Zirakchian Zadeh M, Raynor WY, Ostergaard B, et al. Correlation of whole-bone marrow dual-time-point (18)F-FDG, as measured by a CT-based method of PET\/CT quantification, with response to treatment in newly diagnosed multiple myeloma patients. Am J Nucl Med Mol Imaging. 2020;10(5):257\u201364.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"Supplement 1","key":"1465_CR48","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1182\/blood-2021-150519","volume":"138","author":"M Sebag","year":"2021","unstructured":"Sebag M, Raje NS, Bahlis NJ, et al. Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from magnetismm-1. Blood. 2021;138(Supplement 1):895\u2013895.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1465_CR49","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","volume":"138","author":"S Trudel","year":"2021","unstructured":"Trudel S, Cohen AD, Krishnan AY, et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated Relapsed\/Refractory Multiple Myeloma (RRMM): updated results from an Ongoing Phase I Study. Blood. 2021;138(Supplement 1):157\u2013157.","journal-title":"Blood"},{"issue":"18","key":"1465_CR50","first-page":"1722","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Girgis S, Goldberg JD. Teclistamab in relapsed or refractory multiple myeloma. Reply N Engl J Med. 2022;387(18):1722\u20133.","journal-title":"Reply N Engl J Med"},{"issue":"24","key":"1465_CR51","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232\u201344.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"1465_CR52","doi-asserted-by":"publisher","first-page":"10140","DOI":"10.1182\/blood-2022-159969","volume":"140","author":"N Bumma","year":"2022","unstructured":"Bumma N, Richter J, Brayer J, et al. Updated safety and efficacy of REGN5458, a BCMAxCD3 bispecific antibody, treatment for relapsed\/refractory multiple myeloma: a phase 1\/2 first-in-human study. Blood. 2022;140(Supplement 1):10140\u20131.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1465_CR53","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood-2020-140641","volume":"136","author":"S Mailankody","year":"2020","unstructured":"Mailankody S, Matous JV, Liedtke M, et al. Universal: an allogeneic first-in-human study of the anti-Bcma ALLO-715 and the anti-CD52 ALLO-647 in relapsed\/refractory multiple myeloma. Blood. 2020;136(Supplement 1):24\u20135.","journal-title":"Blood"},{"issue":"4","key":"1465_CR54","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","volume":"28","author":"M Smith","year":"2022","unstructured":"Smith M, Dai A, Ghilardi G, et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med. 2022;28(4):713\u201323.","journal-title":"Nat Med"},{"issue":"8","key":"1465_CR55","doi-asserted-by":"publisher","first-page":"9228","DOI":"10.1002\/cam4.5665","volume":"12","author":"MZ Powell","year":"2023","unstructured":"Powell MZ, Mara KC, Bansal R, et al. Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipients. Cancer Med. 2023;12(8):9228\u201335.","journal-title":"Cancer Med"},{"issue":"6","key":"1465_CR56","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41409-022-01664-z","volume":"57","author":"A Borogovac","year":"2022","unstructured":"Borogovac A, Keruakous A, Bycko M, et al. Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center. Bone Marrow Transplant. 2022;57(6):1025\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"1465_CR57","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/jitc-2020-002056","volume":"9","author":"GD Myers","year":"2021","unstructured":"Myers GD, Verneris MR, Goy A, Maziarz RT. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia. J Immunother Cancer. 2021;9(4):66.","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01465-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01465-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01465-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T10:04:58Z","timestamp":1690797898000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01465-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1465"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01465-x","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,31]]},"assertion":[{"value":"5 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.R. Kite\/Gilead: Research Funding and travel support; Novartis: Honoraria; BMS\/Celgene: Consultancy, Honoraria. D.K.H: Honoraria from OncLive; Consulting or advisory role and Research funding from Bristol-Myers Squibb, and research funding from Adaptive Biotech. DKH is supported by the Pentecost Family Myeloma Research Center and the International Myeloma Society Young Investigator Award. P.S. Kite\/Gilead: travel support; Honoraria; BMS\/Celgene: Consultancy, Honoraria; Chugai: Honoraria; Janssen: travel support; Honoraria. S.A. Celgene: Consultancy; Amgen: Consultancy, Research Funding; Pharmacyclics: Research Funding; Cellectar: Research Funding; Janssen: Consultancy, Research Funding; Takeda: Consultancy. C.L.F. reports honoraria\/consulting roles for BMS, Seattle Genetics, Celgene, Abbvie, Sanofi, Incyte, Amgen, and Janssen; and research funding from Teva, Janssen, and Roche\/Genentech. CLF is supported by the Pentecost Family Myeloma Research Center. M.A. reports consulting or advisory role for Bristol-Myers Squibb and Janssen; Speakers\u2019 bureau for Janssen; honoraria from Janssen. MA is supported by the Pentecost Family Myeloma Research Center. S.T. Honoraria\/Consultancy: Amgen, BMS\/Celgene, GSK, Janssen, Pfizer, Sanofi and Takeda. Y.W. Research funding (to institution): Incyte, InnoCare, LOXO Oncology, Eli Lilly, MorphoSys, Novartis, Genentech, Genmab; Advisory board (compensation to institution): Eli Lilly, LOXO Oncology, TG Therapeutics, Incyte, InnoCare, Kite, Jansen, BeiGene; Honorarium (to institution): Kite A.M.K. Advisory\/Honorary: BMS, Sanofi, Novartis, Roche, Pierre-Fabre, Gilead, Takeda, Pfizer, Jannsen; Research Funding: BMS, Kiadis, Nykode; Travel support: BMS, Sanofi, Pierre-Fabre,Takeda, Janssen, Gilead. F.L. has a scientific advisory role with Kite, a Gilead Company, Novartis, Celgene\/Bristol-Myers Squibb, GammaDelta Therapeutics, Wugen, Amgen, Calibr, and Allogene; is a consultant with grant options for Cellular Biomedicine Group, Inc.; and receives research support from Kite, a Gilead Company, Novartis, and Allogene; and reports that his institution holds unlicensed patents in his name in the field of cellular immunotherapy. E.B. Consultancy\/Honoraria: Novartis, Kite\/Gilead, Roche, Takeda and Incyte; Research funding (paid to institution) from Amgen; and travel and personal feed from Roche and Incyte. M.D.J. Kite\/Gilead: Consultancy\/Advisory, Novartis: Consultancy\/Advisory, BMS: Consultancy\/Advisory, Takeda: Consultancy\/Advisory. Y.L. Research funding: Kite\/Gilead, BMS, Janssen, Merck, Takeda, 2Seventy Bio. consultancy\/advisory: Novartis, BMS, Janssen, Gamida Cells, NexImmune, NekTar Biotherapeutics, Pfizer, Kite\/Gilead. DSMB: Pfizer, Sorrento. All funds to institution, no personal compensation. M.S. Morphosys: Research Funding; Novartis: Consultancy, Research Funding; Janssen: Consultancy; Seattle Genetics: Research Funding; AMGEN: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria; Kite\/Gilead: Consultancy, Honoraria, Research Funding; Roche AG: Consultancy, Research Funding. The remaining authors have nothing to declare. None of the mentioned conflicts of interest were related to financing of the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}